Regarding this, Smeby et al. [132] indicated that a subset of TP53 wild-type CRC cell lines were sensitive to the effect of PARPIs, whereas TP53 inhibition reversed the consequence. This evidence concerns the gene TP53 and colorectal carcinoma.